Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) opnår de primære endpoints i selskabets kliniske fase 2 studie med lægemiddelkandidaten RNX-051.
November 16, 2023 06:17 ET
|
Pharma Equity Group A/S
16. november 2023 Selskabsmeddelelse nr. 45 Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) opnår de primære endpoints i selskabets kliniske fase 2 studie med lægemiddelkandidaten...
Pharma Equity Group’s subsidiary (Reponex Pharmaceuticals A/S) meets the primary endpoints in the phase-2 clinical trial of the drug candidate RNX-051.
November 16, 2023 06:17 ET
|
Pharma Equity Group A/S
16 November 2023 Company Announcement no. 45 Pharma Equity Group’s subsidiary (Reponex Pharmaceuticals A/S) meets the primary endpoints in the phase-2 clinical trial of the drug candidate RNX-051. ...
Konsolideret delårsrapport 1. januar – 30. september 2023
November 16, 2023 02:26 ET
|
Pharma Equity Group A/S
Konsolideret delårsrapport 1. januar – 30. september 2023 16. november 2023 Selskabsmeddelelse nr. 44 Hovedpunkter (ni-måneders rapport afsluttet 30. september 2023) Bestyrelsen og direktionen i...
Consolidated interim report 1 January – 30 September 2023
November 16, 2023 02:26 ET
|
Pharma Equity Group A/S
Consolidated interim report 1 January – 30 September 2023 16 November 2023 Company Announcement no. 44 Key points (nine-month report ended 30 September 2023) On 16 November 2023, the Board of...
Forløb af ekstraordinær generalforsamling i Pharma Equity Group A/S
November 02, 2023 10:14 ET
|
Pharma Equity Group A/S
2. november 2023 Meddelelse nr. 43 Forløb af ekstraordinær generalforsamling i Pharma Equity Group A/S Pharma Equity Group A/S afholdte i dag ekstraordinær generalforsamling, hvor...
Resolutions of the Extraordinary General Meeting of Pharma Equity Group A/S
November 02, 2023 10:14 ET
|
Pharma Equity Group A/S
2 November 2023 Announcement no. 43 Resolutions of the Extraordinary General Meeting of Pharma Equity Group A/S Pharma Equity Group A/S today held its Extraordinary General Meeting with...
Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) modtager EPO meddelelse om udstedelse af patenter på behandling med datterselskabets sårhelende lægemiddelkombination samt behandling mod Colorektal Cancer.
October 31, 2023 08:18 ET
|
Pharma Equity Group A/S
31. oktober 2023 Selskabsmeddelelse nr. 42 Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) modtager European Patent Office (EPO) meddelelse om udstedelse af patent på behandling...
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) receives a notification from the EPO regarding the “Intention to Grant” for patents of the subsidiary's wound-healing drug combination and the treatment of colorectal cancer.
October 31, 2023 08:18 ET
|
Pharma Equity Group A/S
October 31, 2023 Company Announcement No. 42 Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) receives a notification from the European Patent Office (EPO) regarding the...
Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) har modtaget meddelelse om godkendelse af patent på behandling med datterselskabets sårhelende lægemiddelkombination.
October 31, 2023 06:57 ET
|
Pharma Equity Group A/S
31. oktober 2023 Selskabsmeddelelse nr. 41 Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) har modtaget meddelelse om godkendelse af patent på behandling med datterselskabets...
Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) have received grant of US Patent for a method of treatment on its topical wound-healing composition.
October 31, 2023 06:57 ET
|
Pharma Equity Group A/S
31 October 2023 Announcement no. 41 Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) have received grant of US Patent for a method of treatment on its topical wound-healing...